COR vs HSIC: fair value comparison
Cencora, Inc. and Henry Schein, Inc. · Updated 2026-09-07
Both currently screen as fairly valued on TickrTrends' Forward Fair Value model. Within Healthcare, HSIC currently sits closer to the top of our discount ranking.
| COR | HSIC | |
|---|---|---|
| Verdict | Fairly valued | Fairly valued |
| Last price | $330.95 | $89.81 |
| 12-month range | $264.69–$372.65 | $63.20–$88.52 |
| Sector rank | #75 of 113 Healthcare | #70 of 113 Healthcare |
| Quality grade | F | F |
| Leverage | High | Moderate |
| Margin trend | Stable | Stable |
| Revenue growth | Strong | Modest |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | — | Uptrend |
| DCF cross-check | — | Overvalued |
| 52-week position | The upper-middle quarter | The top quarter |
Full single-stock breakdowns: COR fair value analysis · HSIC fair value analysis